Vertically-integrated, growth-oriented life sciences Company Pure Global Cannabis Inc. (TSXV: PURE , OTC: PRCNF , Forum) on Thursday stated that its wholly-owned subsidiary, PureSinse Inc. is anticipating its Access to Cannabis for Medical Purposes Regulations (ACMPR) sales license in the coming weeks.
PURE has also successfully completed the Phase 1 build-out and commenced Phase 2 (18,000 sq ft. facility with 4,000 kg per annum capacity) and Phase 3 (41,000 sq ft. facility with 8,000 kg per annum capacity) simultaneous build-outs with completion expected Q4 2018 and Q1 2019 respectively. The Company also signed a binding LOI with Avicanna Inc. to obtain a 60% interest in Sativa Nativa S.A.S. in Colombia.
More information can be found here .
PURE also made news last week when it purchased a further 210kg of medical cannabis for resale from the Supreme Cannabis Co. PureSince is a licensed producer that has a cultivation license and focuses on R&D & establishing sales.
FULL DISCLOSURE: Pure Global Cannabis Inc. is a paid client of Stockhouse Publishing.